Chenglan Yan
Shanxi Medical University
5 Papers
8 Citations
Chenglan Yan is an academic researcher from Shanxi Medical University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Patent
Marrow puncture needle
Chen Junwei,Zhang Shengxiao,Hao Meihua,Huang Zehao,Ma Xiaowen,Zhang Jundong,Gao Peili,Chenglan Yan,Yang Jinhua,Meng Wu,Wang Jing,Qiao Yue,Liang Zhaoyun,Jing Xiaona,Lian Fenping +14 more
- 21 Sep 2016
TL;DR: In this paper, the utility model relates to a marrow puncture needle, including outer tube and nook closing member, the outer tube is constituteded with an outer bushing portion that is located puncture section of thick bamboo top for the body and by a puncture sections of a thick bamboo, and the bottom of puncture tin is oblique needle point.
5
Vincristine-Cyclophosphamide Combination Therapy Positively Affects T-Cell Subset Distribution in Systemic Lupus Erythematosus Patients
Chen Junwei,Lijuan Ding,Wu Meng,Jinhua Yang,Chenglan Yan,Jianfang Xie,Luo Jing,Xiaofeng Li,Zili Fu +8 more
TL;DR: T-cell subset distributions vary across different levels of SLE disease activity with higher CD3+ T-cell and CD4+ Th cell percentages favoring lower SLE activity and vincristine-cyclophosphamide combination therapy appears to positively affect the T- cell subset distribution in SLE patients to keep the disease in remission.
Absolute decrease in regulatory T cells and low‐dose interleukin‐2 therapy: restoring and expanding regulatory T cells to treat systemic sclerosis: a 24‐week study
TL;DR: It is shown that the absolute numbers of peripheral Treg cells together with total T,CD4+ T, CD8+ T and NK is significantly decreased, leading to an imbalance of Th17 to Treg Cells in patients with SSc, and that low-dose IL-2 treatment could restore the balance of the two immune cells and reduce disease activity without obvious adverse effects.
2
Long-Term Efficacy and Low Adverse Events of Methylprednisolone Pulses Combined to Low-Dose Glucocorticoids for Systemic Sclerosis: A Retrospective Clinical Study of 10 Years’ Follow-Up
TL;DR: It is indicated that intravenous MP-Pulse combined with oral LTLD-GC could achieve significant remission and better long-term efficacy without severe adverse effects in SSc patients with ILD and induration of skin.
Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus
TL;DR: It should be the mechanism that Belimumab combined with low-dose intravenous CYC therapy restores the balance of T and B cells, which proposes a potential treatment strategy for SLE.